Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial

NCT05348915 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05348915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05348915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
March 29, 2022
Completion date
November 7, 2025
Enrollment
242 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease, vaso-occlusive crisis, vaso-occlusive pain episode in sickle cell disease